McIlrath & Eck’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $81.6K | Hold |
585
| – | – | 0.01% | 416 |
|
|
2025
Q4 | $71.9K | Hold |
585
| – | – | 0.01% | 294 |
|
|
2025
Q3 | $65K | Hold |
585
| – | – | 0.01% | 270 |
|
|
2025
Q2 | $64.9K | Hold |
585
| – | – | 0.01% | 268 |
|
|
2025
Q1 | $65.6K | Hold |
585
| – | – | 0.01% | 260 |
|
|
2024
Q4 | $54.1K | Hold |
585
| – | – | 0.01% | 287 |
|
|
2024
Q3 | $49.1K | Hold |
585
| – | – | 0.01% | 313 |
|
|
2024
Q2 | $40.2K | Sell |
585
-196
| -25% | -$13.1K | 0.01% | 313 |
|
|
2024
Q1 | $57.2K | Buy |
781
+231
| +42% | +$17.8K | 0.01% | 250 |
|
|
2023
Q4 | $44.6K | Buy |
550
+221
| +67% | +$17.2K | 0.01% | 270 |
|
|
2023
Q3 | $24.7K | Sell |
329
-407
| -55% | -$31.3K | 0.01% | 370 |
|
|
2023
Q2 | $56.7K | Hold |
736
| – | – | 0.01% | 231 |
|
|
2023
Q1 | $61.1K | Hold |
736
| – | – | 0.01% | 218 |
|
|
2022
Q4 | $63.2K | Buy |
736
+173
| +31% | +$13.7K | 0.02% | 210 |
|
|
2022
Q3 | $35K | Buy |
563
+58
| +11% | +$3.66K | 0.01% | 306 |
|
|
2022
Q2 | $31K | Sell |
505
-71
| -12% | -$4.4K | 0.01% | 313 |
|
|
2022
Q1 | $34K | Sell |
576
-5
| -0.9% | -$320 | 0.01% | 306 |
|
|
2021
Q4 | $42K | Hold |
581
| – | – | 0.01% | 270 |
|
|
2021
Q3 | $41K | Buy |
581
+1
| +0.2% | +$70 | 0.01% | 260 |
|
|
2021
Q2 | $40K | Buy |
580
+1
| +0.2% | +$67 | 0.01% | 263 |
|
|
2021
Q1 | $37K | Hold |
579
| – | – | 0.01% | 240 |
|
|
2020
Q4 | $34K | Buy |
579
+1
| +0.2% | +$60 | 0.01% | 221 |
|
|
2020
Q3 | $37K | Buy |
578
+12
| +2% | +$832 | 0.02% | 181 |
|
|
2020
Q2 | $44K | Buy |
566
+94
| +20% | +$7.2K | 0.02% | 142 |
|
|
2020
Q1 | $35K | Buy |
472
+248
| +111% | +$17.1K | 0.02% | 148 |
|
|
2019
Q4 | $15K | Hold |
224
| – | – | 0.01% | 284 |
|
|
2019
Q3 | $14K | Sell |
224
-61
| -21% | -$3.99K | 0.01% | 275 |
|
|
2019
Q2 | $18K | Hold |
285
| – | – | 0.01% | 209 |
|
|
2019
Q1 | $18K | Buy |
285
+1
| +0.4% | +$66 | 0.01% | 209 |
|
|
2018
Q4 | $18K | Sell |
284
-32
| -10% | -$2.24K | 0.01% | 199 |
|
|
2018
Q3 | $24K | Buy |
316
+52
| +20% | +$3.93K | 0.01% | 188 |
|
|
2018
Q2 | $19K | Sell |
264
-843
| -76% | -$59.5K | 0.01% | 208 |
|
|
2018
Q1 | $83K | Sell |
1,107
-684
| -38% | -$54.4K | 0.05% | 92 |
|
|
2017
Q4 | $128K | Buy |
+1,791
| New | +$136K | 0.08% | 75 |
|
Other funds holding GILD
McIlrath & Eck's GILD Position: Q1 2026 in Review
McIlrath & Eck held its Gilead Sciences (GILD) position steady in Q1 2026 at 585 shares worth $81.6K. The position accounts for 0.01% of the portfolio, ranked #416.
McIlrath & Eck first reported a position in GILD in Q4 2017 and has held it in 34 quarters since. The position peaked at $128K in Q4 2017. 2,320 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- McIlrath & Eck held 585 shares of Gilead Sciences worth $81.6K as of Q1 2026.
- McIlrath & Eck left its Gilead Sciences share count unchanged in Q1 2026.
- Gilead Sciences made up 0.01% of McIlrath & Eck's portfolio in Q1 2026, its #416 holding.
- McIlrath & Eck first reported a position in Gilead Sciences in Q4 2017 and has held it in 34 quarters since.
- McIlrath & Eck's Gilead Sciences position peaked at $128K in Q4 2017.
- 2,320 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.